The I-SPY 2 trial was featured in the March 22, 2010 issue of BioCentury, The Bernstein Report on BioBusiness. Download a PDF of the article, which details the development of this innovative trial design, and how partnership between the NCI, FDA, pharmaceutical companies, academic cancer centers, and the FNIH Biomarkers Consortium was instrumental in the formation of this unique project. Multiple biomarkers and anti-cancer agents from different companies will be studied together in this personalized medicine project.